What caused the significant swing from a net loss in Q2 2006 to a net income in Q2 2007?

The substantial improvement from a net loss in Q2 2006 to a net income in Q2 2007 was primarily due to the absence of large, one-time charges recorded in the prior year. These charges were related to purchase accounting adjustments for inventory and acquired research and development associated with the Guidant acquisition, as well as acquisition-related costs. In Q2 2007, these significant charges were not present, allowing the company to report a profit.

What are the main challenges facing the coronary stent business, particularly drug-eluting stents?

The coronary stent business, especially drug-eluting stents (DES), faces challenges including concerns about late stent thrombosis, which has led to a decline in the U.S. DES market size and reduced penetration rates. Increased competition, with new product launches by competitors, is also impacting market share and average selling prices, particularly in international markets. The company anticipates continued pressure on U.S. DES sales until the market stabilizes.

What is the status of the Cardiac Rhythm Management (CRM) business and its regulatory issues?

The CRM business experienced a slight pro forma sales decrease in Q2 2007, attributed to physician response to a product advisory. However, the company has resolved a corporate warning letter with the FDA related to CRM facilities, with FDA inspectors noting no additional observations during reinspections. This resolution is considered a major milestone to rebuild trust and confidence in the CRM product offerings and allows for a resumption of new product introductions.

What is the company's outlook on its debt and credit rating?

As of June 30, 2007, Boston Scientific was in compliance with its debt covenants. However, in July and August 2007, credit ratings were downgraded to non-investment grade by Moody's, S&P, and Fitch. The company stated it does not expect these downgrades to materially increase its cost of borrowing, but acknowledges potential impacts on borrowing costs. The company is also exploring strategic initiatives, including asset sales, to increase cash for debt repayment.

BSX 10-Q Quarterly Report Q2 FY2007 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) reported a 2% decrease in net sales for the second quarter of 2007, totaling $2.071 billion, compared to $2.110 billion in the prior year. However, the company significantly improved its profitability, reporting a net income of $115 million ($0.08 per diluted share) compared to a net loss of $4.262 billion ($3.21 per diluted share) in the same period of 2006. This dramatic turnaround is largely attributed to substantial one-time charges recorded in Q2 2006 related to the Guidant acquisition, primarily purchase accounting adjustments and integration costs. For the first half of 2007, net sales grew by 11% to $4.157 billion, reflecting the full inclusion of the Cardiac Rhythm Management (CRM) and Cardiac Surgery businesses. Net income for the first half was $235 million ($0.16 per diluted share), a substantial improvement from the net loss of $3.930 billion ($3.66 per diluted share) in the comparable period of 2006. The company faces ongoing challenges in its coronary stent business, particularly in the U.S. due to declining market size and concerns about late stent thrombosis. Efforts are underway to regain trust and recover sales in the CRM business following product advisories and regulatory resolutions.

Key Highlights

1Q2 2007 Net Sales decreased 2% to $2.071 billion, while H1 2007 Net Sales increased 11% to $4.157 billion.
2Reported a net income of $115 million ($0.08/share) for Q2 2007, a significant improvement from a net loss of $4.262 billion ($3.21/share) in Q2 2006, largely due to one-time charges in the prior year.
3U.S. coronary stent sales declined significantly in Q2 2007, driven by a shrinking market size for drug-eluting stents and reduced procedure volumes.
4International coronary stent sales also saw declines due to increased competition, though Japan showed strong growth following a new product launch.
5The Cardiac Rhythm Management (CRM) business experienced a 1% pro forma sales decrease in Q2 2007, attributed to physician reaction to a product advisory, though international CRM sales grew.
6The company reported compliance with debt covenants as of June 30, 2007, but credit ratings were downgraded to non-investment grade in July/August 2007.
7Regulatory efforts continue, with the company believing it has resolved warning letter issues and is awaiting FDA reinspection.

BOSTON SCIENTIFIC CORP Quarterly Report for Q2 Ended Jun 30, 2007

Summary

Key Highlights

Frequently Asked Questions